Author: Ben Debski

Based in the German university town of Jena, JenLab provides femtosecond laser technology for a range of critical lab and theatre applications in biotechnology, medicine and cell biology.

As an innovator in the field of diagnostic genetics, Color Genomics offers patients affordable genetic testing in order to help determine their level of risk to common hereditary types of cancer.

As Medical Director of the US National Parkinson Foundation, Dr Michael Okun is a driving force in the fight against movement disorders in general, and specifically Parkinson’s disease.

Researchers at the University of Melbourne have transferred lab-grown corneas into the eyes of blind mice, curing them of the affliction. The research is now ready for human trials.

Offering a desperately needed solution to people in remote, war-torn and desert areas, the Wyss Institute’s pioneering portable vaccine kit works without refrigeration and can be rehydrated for immediate use.

A clinical stage biopharmaceutical company located in Barcelona, Oryzon Genomics is one of Europe’s leaders in the development of epigenetics-based therapeutic treatments.

Aquinnah Pharmaceuticals’ innovative approach has helped it develop a new drug therapy to arrest and potentially reverse the effects of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

As leaders in image-guided therapy, Philips Volcano provides a range of integrated solutions that allow enhanced, bespoke treatments to be provided for each and every patient.

Antibiotic resistance is one of the greatest existential threats in the modern world. This transatlantic, public-private partnership will plough $30m into the area in its first year alone, boosting humanity’s odds in the fight.

Based in Indonesia, Garbage Clinical Insurance is an innovative micro-health insurance programme that allows patients to trade recycling for free healthcare, helping the environment and the population at the same time.

A veteran of the biopharmaceutical industry, since joining Chiasma in 2015, Leuchtenberger has steered the company’s commercialisation of octreotide capsules for the treatment of acromegaly.

Tech giant Microsoft has turned its attention to cellular reprogramming solutions, setting itself the ambitious task of curing cancer within a single decade. It aims to do this by reprogramming cancerous cells.